The DEA's Recreational Marijuana Hearing Has Begun: What Employers Need to Know Right Now

What the DEA Hearing Covers

The Federal Register notice initiating this rulemaking established the scope: whether marijuana that does not qualify under the existing medical rescheduling order should be moved from Schedule I (high abuse potential, no accepted medical use) to Schedule III (moderate abuse potential, accepted medical use with restrictions).

Key procedural points employers should understand:

• Only opponents testify first. Under DEA administrative hearing rules, only parties opposed to rescheduling were permitted to present testimony during the initial phase. Pro-reform groups including NORML and the National Cannabis Industry Association were excluded from presenting during this stage.
• The hearing is evidence-gathering, not decision-making. The administrative law judge will compile a record and issue recommended findings. The final decision rests with the DEA Administrator.
• No final rule is imminent. After the hearing closes on July 15, months of deliberation, public comment review, and final rulemaking remain before any scheduling change takes effect.

What Has Already Changed (and What Has Not)

Employers operating in 2026 face a split federal framework that did not exist a year ago:

This split creates confusion, but the compliance message is clear: recreational marijuana remains federally illegal. Employers retain full authority to test for THC and take adverse action on positive results, subject to applicable state law.

The State Law Layer: July 1 Deadlines

Compounding the federal uncertainty, several state and local employment laws take effect on July 1, 2026, many of which affect marijuana-related employment practices:

• California continues to prohibit employers from discriminating against applicants based on off-duty cannabis use (under AB 2188, effective since 2024), and new local minimum wage increases may prompt broader handbook reviews.
• New York maintains its prohibition on pre-employment marijuana testing for most non-safety-sensitive roles.
• Nevada restricts adverse action based solely on pre-employment marijuana test results for non-safety-sensitive positions.
• Connecticut, Washington, and Montana each maintain protections for employees' off-duty recreational cannabis use that limit employer testing authority.

Employers operating in multiple states face a compliance matrix that grows more complex with each legislative session. The federal hearing adds another variable—but does not change current state-level obligations.

What This Means for Employer Drug Policies

Immediate Actions (Now Through July 15)

1. Do not change your testing program based on the hearing alone. The proceeding is administrative and advisory. No federal rule has changed for recreational cannabis.

2. Audit your policy language. Review drug-free workplace policies for references to marijuana as a "Schedule I substance" or "federally illegal drug." If the April medical rescheduling already made some of this language inaccurate, the recreational hearing adds urgency to updates. Replace scheduling-specific language with terms like "prohibited substances" or "substances that impair safe job performance."

3. Confirm state compliance. With July 1 deadlines approaching, verify that testing protocols and adverse action procedures comply with every state where you have employees—particularly California, New York, Connecticut, Nevada, Washington, and Montana.

4. Brief supervisors and HR. Employees will ask questions. Prepare talking points that distinguish between what the hearing is (a procedural step) and what it is not (a legalization event or policy change).

Contingency Planning (Post-Hearing)

If the DEA ultimately reschedules recreational marijuana to Schedule III, employers should be prepared for several downstream effects:

• ADA accommodation requests will increase. Schedule III classification strengthens the argument that marijuana has "accepted medical use," which may open the door to more disability accommodation claims involving cannabis.
• State legislatures will accelerate protections. A federal Schedule III classification for recreational cannabis would likely embolden additional states to restrict employer testing authority.
• Insurance and workers' compensation implications will shift. Carriers may revisit policies around marijuana-related claims if federal classification changes.
• "Impairment-based" testing gains momentum. The industry trend toward testing for active impairment rather than mere presence of THC metabolites will accelerate as the legal foundation for zero-tolerance policies narrows.

What Will Not Change (Regardless of Outcome)

Even if recreational marijuana moves to Schedule III:

• DOT testing requirements remain. The Department of Transportation's testing mandate is statutory. Schedule III substances like certain prescription drugs already appear on DOT panels—marijuana would simply remain there under a different classification.
• Safety-sensitive positions retain testing authority. Employers in transportation, healthcare, construction, energy, and other safety-critical sectors will maintain testing authority under federal law and most state laws.
• Drug-Free Workplace Act obligations persist. The Act requires federal contractors to maintain drug-free workplace policies but does not mandate testing. Its requirements are independent of CSA scheduling.

The Dual-Framework Challenge

The April 2026 rescheduling order created what legal commentators have called a "dual framework"—the same plant is simultaneously Schedule I (recreational) and Schedule III (medical) depending on its intended use and distribution channel. This framework creates real compliance challenges:

• An employee with a state medical marijuana card may argue their use falls under the Schedule III classification and warrants accommodation.
• An employee using identical cannabis products recreationally has no such argument under current federal law.
• Employers must now track not just whether an employee tests positive, but potentially why they used the substance—a distinction many testing programs were never designed to make.

For practical guidance on navigating these dual-framework challenges within a drug-free workplace program that maintains both compliance and employee trust, BlueHive's white paper "Drug Free Doesn't Mean Compassion-Free" offers a framework for balancing safety obligations with supportive, stigma-reducing practices.

Timeline and What to Watch

Employers should monitor the DEA's marijuana rescheduling regulatory actions page for updates, hearing transcripts, and eventual rulemaking documents.

Bottom Line

The DEA hearing that opened on June 29 is historic, but it is not a compliance emergency—yet. Recreational marijuana remains Schedule I today. Employer testing programs remain lawful. DOT mandates remain in force.

What employers should do is prepare: audit policy language, verify multi-state compliance, plan for the accommodation questions that rescheduling would trigger, and build flexibility into drug-free workplace programs that may need to pivot from zero-tolerance models toward impairment-based frameworks.

The hearing is the beginning of a process, not the end of one. Employers who use this window to get ahead of the change—rather than reacting to it—will be in the strongest compliance position regardless of the outcome.

Sources

• DEA Press Release: Hearing on Proposed Marijuana Rescheduling Begins June 29
• DOJ: Justice Department Places FDA-Approved Marijuana Products on Schedule III
• Federal Register: Schedules of Controlled Substances—Rescheduling of Marijuana
• Federal Register: Rescheduling of FDA-Approved Marijuana Products
• DEA Marijuana Rescheduling Regulatory Actions
• Fisher Phillips: Employer Cheat Sheet for Workplace Laws Taking Effect July 1, 2026
• Forbes: DEA Kicks Off Historic Hearing On Cannabis Rescheduling Proposal
• BlueHive White Paper: Drug Free Doesn't Mean Compassion-Free